What Are Peptides?

A peptide is a chain of amino acids linked by peptide bonds. The cutoff between "peptide" and "protein" is fuzzy in practice, but a useful working definition is roughly 2 to 50 amino acids. Insulin, at 51 residues across two chains, sits right on the boundary and is often described either way depending on the audience.

What distinguishes the class is not its chemistry but its role. Where a small molecule drug is typically an enzyme inhibitor or receptor modulator designed in a lab, most therapeutic peptides mimic — or are identical to — signaling molecules the body already makes. They are the language cells use to talk to each other.

A small-molecule drug like ibuprofen works by inhibiting an enzyme (COX-1/2) everywhere in the body at once. The effect is broad because the mechanism is broad. Peptides generally work differently: they bind to a specific receptor on a specific cell type, and the downstream effect is whatever that receptor was already wired to do.

GLP-1 peptides bind the GLP-1 receptor on pancreatic beta cells and in brainstem satiety centers. BPC-157 appears to act on angiogenic and growth-factor signaling at injury sites. GHK-Cu coordinates copper and modulates thousands of wound-healing genes in skin. The pattern is consistent: narrow receptor, specific tissue, defined downstream cascade.

This is why peptides are often described as "precision" — not because they are inherently safer, but because the mechanism itself is tissue- and receptor-specific rather than systemic.

Most clinical-grade peptides are delivered by subcutaneous or intramuscular injection because the gut degrades peptide bonds before absorption. A small number are orally bioavailable (MK-677, a small molecule often grouped with peptides; certain cyclic peptides engineered for stability), and a handful work intranasally (semax, selank) by exploiting direct nasal-to-brain transport.

Research papers typically report peptide exposure in terms of receptor affinity (Kd / EC50), pharmacokinetics (half-life, Tmax, Cmax), and downstream biomarker movement rather than blanket "effectiveness." The STEP-1 trial for semaglutide, for example, is reported as mean percent weight loss across a 68-week titration arm — not a single dose claim.

Access and legality varies dramatically by compound and by jurisdiction. Some peptides are fully FDA-approved drugs (semaglutide, tirzepatide). Others are in active clinical development. Many are sold only as research-use chemicals and are not approved for human administration. Always verify the regulatory status of any specific compound in your jurisdiction.